Artelo Biosciences (NASDAQ:ARTL) Upgraded by LADENBURG THALM/SH SH to “Strong-Buy” Rating

LADENBURG THALM/SH SH upgraded shares of Artelo Biosciences (NASDAQ:ARTL) to a strong-buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. EF Hutton Acquisition Co. I raised Artelo Biosciences to a “strong-buy” rating in a research report on Tuesday, October 1st. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Artelo Biosciences in a report on Monday, December 9th. Finally, D. Boral Capital restated a “buy” rating and issued a $6.00 price objective on shares of Artelo Biosciences in a research note on Monday, December 9th.

Artelo Biosciences Stock Up 1.4 %

NASDAQ:ARTL opened at $1.06 on Wednesday. The company’s 50 day moving average is $1.11 and its 200-day moving average is $1.21. Artelo Biosciences has a 12 month low of $0.91 and a 12 month high of $1.75. The firm has a market cap of $3.42 million, a price-to-earnings ratio of -0.37 and a beta of 1.29.

Artelo Biosciences (NASDAQ:ARTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.06. Research analysts predict that Artelo Biosciences will post -2.62 EPS for the current fiscal year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.